78% objective mitigation rate The clinical results of new treatment sedatives for refractory children with cerebral tumors are positive

Neuroblastoma is one of the most common cancers in infants and young childrenIt is a highly invasive tumor, and even with highly potent treatments, the patient's survival rate is less than 50%Osteosarcoma is a malignant bone tumor common in children, common lying at the end of the long boneAlthough the treatment of osteosarcoma has improved greatly in recent years, the improvement in patients' survival has been very limitedNaxitamab is a humanoid monoclonal antibody that targets GD2 antigensGD2 antigens are expressed on tumor surfaces produced in the neuroblastoma layer, including neuroblastoma, melanoma and osteosarcomaBy binding to GD2 antigens on the tumor surface, Naxitamab can trigger a cytotoxic reaction of antibody vectors and activate the immune system's complement system to kill tumorsIt has been granted fda certification for the treatment of neuroblastoma and osteosarcoma, and breakthrough therapy has been identified as a combination of high-risk neuroblastomas with GM-CSFCurrently, the drug is used in clinical trials to treat children with recurrent/difficult-treatment high-risk neuroblastoma, osteosarcoma, and other GD2-positive tumorsNaxitamab's mechanism of action (Photo: Y-mAbs official website)in the first group of children with neuroblastoma in a phase 1/2 clinical trial called 12-230, 28 patients at high risk of recurrent/difficult treatment who were not eligible for induced chemotherapy received a combination of naxitamab and GM-CSF, and more than half of them were also less likely to receive second-line chemotherapyTrial data show that the combination of therapies resulted in a 78% objective remission rate (ORR) for patients and a 24-month non-progressive survival (PFS) in 50% of patientsin the subgroup of children with neuroblastoma in the second group of 12-230 trials, 30 patients who received salvage therapy but did not perform well received a combination of naxitamab and GM-CSF, with one-third having relapsed more than twice and 89 percent receiving anti-GD2Trial data show that the combination of therapies caused 37% of patients to have ORR and 36% of patients with PFS to 24 months, providing significant clinical benefits for patients with this type of incurable typethe combination of therapies showed good safety in a phase 2 trial called 15-096 for the treatment of recurrent osteosarcoma in children's progress in clinical development in Naxitamab (Photo: Y-mAbs.com)"We are pleased to be able to observe excellent objective remission rates in patients in the 12-230 trial." At the same time, we are very pleased with the duration of the patient's remission, which is consistent with the results we observed in another international multi-center 201 trial, which is critical to our application for a biologiclicense," said DrClaus Moller, CEO of Y-mAbsReferences:https://